"Tenaya Therapeutics recently reported its Q2 2025 financial results, which may influence investor sentiment amid ongoing discussions about its stock performance and potential for future growth. However, analysts have raised concerns about possible pullbacks, highlighting risks associated with market momentum and the stock's defensive positioning."